Board of Directors
Chairman of the Board
Former CEO & Chairman, DJO Global (NYSE:DJO)
Former CEO & Chairman, Alphatec Spine (NASDAQ:ATEC)
Les Cross focused on acquisition and integration as a means of strategic growth during his tenure as CEO of DJO Global, resulting in significant returns and a lucrative private equity exit to Blackstone. His extensive US capital market and medical device company acquisition experience will be the driving energy behind the acquisition of companies in the pipeline.
He led the IPO of DJO Global, raising US$150 million and the sale of DJO Global to Blackstone for US$1.6 billion
Vice-Chair of the Board
Chair of the Audit Committee
Former CEO, Salter Labs
Former Chair of the Audit Committee and Director, American Medical Systems (NASDAQ:AMMD);
Jane Kiernan is an expert in healthcare management, growth, and corporate oversight. Her experience in the sale of American Medical Systems have given her substantial buy and sell side experience and familiarity with the current opportunities in the medical healthcare space.
Ken Kashkin, MD
COO of Chromocell Corporation
Former CMO, Ferring Pharma (Valued at over US$1B)
Former Sen. Executive at Abbot Laboratories (NYSE:ABT)
Former Vice President at Baxter (NYSE: BAX)
Former Professor, Yale University Medical School
Dr. Ken Kashkin brings over 30 years of experience in medical devices, research and development, and corporate governance to the board. An expert physician, Dr. Kashkin serves as a technical medical expert on all transactions for the Company. Dr. Kashkin received his undergraduate and medical degrees from University of California, Los Angeles and completed his education at the Yale University School of Medicine.
Former Senior Manager at Baxter (NYSE: BAX)
Former Senior Manager at Shire (NASDAQ: SHPG)
Former Executive Director, Montgomery Pacific Group
Former U.S. Naval Officer
Kyle Wilks graduated from the US Naval Academy at Annapolis. After his time as a Naval Officer, he worked at Montgomery Pacific Group, a mid market healthcare private equity group as an Executive Director managing portfolio companies. A former senior manager at Baxter in the rare immune deficiency therapies division, and Shire in the rare disease division, he was later a professor of Leadership at the US Naval Academy. He has substantial expertise in finance, leadership and management; medical device and biologics manufacturing and global healthcare market strategy.
Salona's board and management team brings decades of combined experience in medical device M&A and operational integration. Management's deep industry connections have created a deep and robust pipeline of potential acquisition targets.
The Company has retained Michael Dalsin (Former Chairman of PHM) and Roger Greene (Former Vice Chairman of PHM, Harvard Law School, JD) as industry advisors.
In addition to the board and advisor driven pipeline, the internal M&A team in the California corporate office systematically searches for potential acquisition targets globally. The internal acquisition team is structured around the key metrics and infrastructure that drove both DJO Global and PHM to success. Using a well-honed 12 point process, our internal M&A team has developed and continues to develop a deep pipeline of acquisition targets.